Molecular analysis of the CYP2F1 gene: Identification of a frequent non-functional allelic variant

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 617, Issue 1-2, 2007, Pages 79-89

  Tournel, Gilles ^a   Cauffiez, Christelle ^a   Billaut Laden, Ingrid ^a   Allorge, Delphine ^a   Chevalier, Dany ^a   Bonnifet, Fabien ^a   Mensier, Eric ^c   Lafitte, Jean Jacques ^b   Lhermitte, Michel ^a   Broly, Franck ^a   Lo Guidice, Jean Marc ^a  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Hôpital privé La Louvière   (France)

Author keywords

CYP2F1; Genetic polymorphism; Lung cancer; SSCP

Indexed keywords

ASPARAGINE; ASPARTIC ACID; CYTOCHROME P450; CYTOCHROME P450 2F1; GENOMIC DNA; GLUTAMINE; HISTIDINE; UNCLASSIFIED DRUG;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER GENETICS; CAUCASIAN; CONTROLLED STUDY; CYP2F1 1 GENE; CYP2F1 2A GENE; CYP2F1 2B GENE; CYP2F1 3 GENE; CYP2F1 4 GENE; CYP2F1 5A GENE; CYP2F1 5B GENE; CYP2F1 6 GENE; CYP2F1 GENE; DISEASE PREDISPOSITION; DNA FLANKING REGION; ENZYME ACTIVITY; FRAMESHIFT MUTATION; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HOMOZYGOTE; HUMAN; HUMAN TISSUE; INTRON; LUNG CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SINGLE STRAND CONFORMATION POLYMORPHISM; STOP CODON;

EID: 33847721859     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2007.01.007     Document Type: Article

References (35)

1. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C., and Nebert D.W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6 (1996) 1-42
2. Pelkonen O., and Raunio H. Metabolic activation of toxins: tissue-specific expression and metabolism in target organs. Environ. Health Perspect. 105 4 (1997) 767-774
3. Kikkawa Y. Diverse role of pulmonary cytochrome P-450 monooxygenase. Lab. Invest. 5 (1992) 535-539
4. Bond J.A. Metabolism and elimination of inhaled drugs and airborne chemicals from the lung. Pharmacol. Toxicol. 72 (1993) 36-47
5. Hukkanen J., Pelkonen O., and Raunio H. Expression of xenobiotic-metabolizing enzymes in human pulmonary tissue: possible role in susceptibility for ILD. Eur. Respir. J. 18 32 (2001) 122-126
6. Hukkanen J., Pelkonen O., Hakkola J., and Raunio H. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. Crit. Rev. Toxicol. 32 5 (2002) 391-411
7. Chen N., Whitehead S.E., Caillat A.W., Gavit K., Isphording D.R., Kovacevic D., McCreary M.B., and Hoffman S.M. Identification and cross-species comparisons of CYP2F subfamily genes in mammals. Mutat. Res. 499 (2002) 155-161
8. Nhamburo P.T., Kimura S., Mcbride O.W., Kozak C.A., Gelboin H., and Gonzalez F.J. The human CYP2F gene subfamily: identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression, and chromosome mapping. Biochemistry 29 (1990) 5491-5499
9. Lanza D.L., Code E., Crespi C.L., Gonzalez F.J., and Yost G.S. Specific dehydrogenation of 3-methylindole and epoxidation of naphthalene by recombinant human CYP2F1 expressed in lymphoblastoid cells. Drug Metab. Dispos. 27 (1999) 798-803
10. Wang H., Lanza D., and Yost G. Cloning and expression of CYP2F3 a cytochrome P450 that bioactivates the selective pneumotoxins 3-methylindole and naphthalene. Arch. Biochem. Biophys. 349 (1998) 894-900
11. Nichols W.K., Mehta R., Skordos K., Macé K., Pfeifer A.M.A., Carr B.A., Minko T., Burchiel S.W., and Yost G.S. 3-Methylindole-induced toxicity to human bronchial epithelial cell lines. Toxicol. Sci. 71 (2003) 229-236
12. Lanza D.L., and Yost G.S. Selective dehydrogenation/oxygenation of 3-methylindole by cytochrome p450 enzymes. Drug Metab. Dispos. 29 7 (2001) 950-953
13. Baldwin R.M., Shultz M.A., and Buckpitt A.R. Bioactivation of the pulmonary toxicants naphthalene and 1-nitronaphtalene by rat CYP2F4. J. Pharmacol. Exp. Ther. 312 2 (2005) 857-865
14. Nakajima T., Elovaara E., Gonzalez F.J., Gelboin H.V., Raunio H., Pelkonen O., Vainio H., and Aoyama T. Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450. Chem. Res. Toxicol. 7 (1994) 891-896
15. Sheets P.L., Yost G.S., and Carlson G.P. Benzene metabolism in human lung cell lines BEAS-2B and A549 and cells overexpressing CYP2F1. J. Biochem. Mol. Toxicol. 18 (2004) 92-99
16. Carr B.A., Wan J., Hines R.N., and Yost G.S. Characterization of the human lung CYP2F1 gene and identification of a novel lung-specific binding motif. J. Biol. Chem. 278 (2003) 15473-15483
17. Wan J., Carr B.A., Cutler N.S., Lanza D.L., Hines R.N., and Yost G.S. SP1 and SP3 regulate basal transcription of the human CYP2F1 gene. Drug Metab. Dispos. 33 8 (2005) 1244-1253
18. Guengerich F.P. Pharmacogenomics of cytochrome P450 and other enzymes involved in biotransformation of xenobiotics. Drug Dev. Res. 49 1 (2000) 4-16
19. Orita M., Iwahana H., Kanazawa H., Hayashi K., and Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc. Natl. Acad. Sci. 86 (1989) 2766-2770
20. Broly F., Marez D., Sabbagh N., Legrand M., Millecamps S., Lo-Guidice J.M., Boone P., and Meyer U.A. An efficient strategy for detection of known and new mutations of CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 5 (1995) 373-384
21. Marez D., Legrand M., Sabbagh N., Lo-Guidice J.M., Spire C., Lafitte J.J., Meyer U.A., and Broly F. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7 (1997) 193-202
22. Lo Guidice J.M., Allorge D., Cauffiez C., Chevalier D., Lafitte J.J., Lhermitte M., and Broly F. Genetic polymorphism of the human cytochrome P450 CYP4B1: evidence for a non-functional allelic variant. Pharmacogenetics 12 (2002) 367-374
23. Chevalier D., Cauffiez C., Bernard C., Lo Guidice J.M., Allorge D., Fazio F., Ferrari N., Libersa C., Lhermitte M., D'Halluin J.C., and Broly F. Characterization of new mutations in the coding sequence and 5'-untranslated region of the human prostacycline synthase gene (CYP8A1). Hum. Genet. 108 2 (2001) 148-155
24. Chevalier D., Lo Guidice J.M., Sergent E., Allorge D., Debuysere H., Ferrari N., Libersa C., Lhermitte M., and Broly F. Identification of genetic variants in the human thromboxane syntahse gene (CYP5A1). Mutat. Res. 432 3-4 (2001) 61-67
25. Cauffiez C., Lo-Guidice J.M., Chevalier D., Allorge D., Hamdan R., Lhermitte M., Laffitte J.J., Colombel J.F., Libersa C., and Broly F. First report of a genetic polymorphism of the cytochrome P450 3A43 (CYP3A43) gene: identification of a loss-of-function variant. Hum. Mutat. 23 (2004) 101
26. Cauffiez C., Klinzig F., Rat E., Tournel G., Allorge D., Chevalier D., Lovecchio T., Pottier N., Colombel J.F., Lhermitte M., D'Halluin J.C., Broly F., Lo J.M., and Guidice. Functional characterization of genetic polymorphisms identified in the human cytochrome P450 4F12 (CYP4F12) promoter region. Biochem. Pharmacol. 67 12 (2004) 2231-2238
27. Cauffiez C., Lo Guidice J.M., Quaranta S., Allorge D., Chevalier D., Cenee S., Hamdan R., Lhermitte M., Lafitte J.J., Libersa C., Colombel J.F., Stucker I., and Broly F. Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility. Biochem. Biophys. Res. Commun. 317 (2004) 662-669
28. Hayashi K., and Yandell Y.W. How sensitive is PCR-SSCP?. Hum. Mutat. 2 (1993) 338-346
29. Mani C., Selvakumar N., Kumar V., Narayanan S., and Narayanan P.R. Comparison of DNA sequencing, PCR-SSCP and PhaB assays with indirect sensitivity testing for detection of rifampicin resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 7 (2003) 652-659
30. Kagimoto K., Heim M., Zeugin T., and Meyer U.A. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional signifiance of individual mutations by expression of chimeric genes. J. Biol. Chem. 265 28 (1990) 17209-17214
31. Saxena R., Shaw G.L., Relling M.V., Frame J.N., Moir D.T., Evans W.E., Caporaso N., and Weiffenbach B. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum. Mol. Genet. 3 6 (1994) 923-926
32. Lewis D.F.V. Essential requirements for substrate brundary affinity and selectivity toward human CYP 2 family enzymes. Archiv. Biochem. Biophys. 409 1 (2003) 32-44
33. J.H. Jiang, Z. Li, G. Su, W.H. Jia, R.H. Zhang, X.J. Yu, M. Zhang, J.M. Wen, Y.X. Zeng. Study on genetic polymorphisms of CYP2F1 gene in Guangdong population of China, Zhonghua. Yi. Xue. Yi. Chuan. Xue. Za. Zhi. 23(4) (2006) 383-387.
34. Shields P.G. Molecular epidemiology of lung cancer. Ann. Oncol. 10 5 (1999) 7-11
35. Kiyohara C., Otsu A., Shirakawa T., Fukuda S., and Hopkin J.M. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer 37 3 (2002) 241-256